Biogen Idec Reports Positive Data From AVONEX Dose Titration Study At 2011 Annual Meeting Of The Consortium Of Multiple Sclerosis Centers
Links shared publicly online about this topic.
- 238total visits
Biogen Idec Reports Positive Data From AVONEX Dose Titration Study At 2011 Annual Meeting Of The Consortium Of Multiple Sclerosis Centers
Biogen Idec (NASDAQ: BIIB) today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX®(interferon beta-1a) dose titration, or
View full resource at medicalnewstoday.com
Tags: Multiple Sclerosis, Multiple Sclerosis Medication, Clinical Trial, Avonex, Biogen Idec
Most Recently Shared on June 7, 2011 at 5:10 am By:
Biogen Idec Reports Positive Data From AVONEX Dose Titration Study At 2011 Annual Meeting Of The Consortium Of M... http://bit.ly/lUcqNZ
Also Shared By:
Biogen Idec Reports Positive Data from AVONEX Dose Titration Study at 2011 Annual Meeting of the Consortium of Multiple Sclerosis Centers - Drugs.com MedNews
drugs.com — “-Data Show that Titrating AVONEX at Initiation of Treatment Reduced Severity of Flu-like Symptoms- Jun 6, 2011 - Biogen Idec (NASDAQ BIIB) today announced the f” View full resource at drugs.com
Most Recently Shared on June 6, 2011 at 2:07 pm By:
Drugs and Devices OW OW Health
Biogen Idec Reports Positive Data from AVONEX Dose Titration Study at 2011 Annual Meeting of the Consortiu... http://bit.ly/mJMKtF #drug
Advertisement
MNT Multiple Scl
@mnt_multiplescl
Biogen Idec Reports Positive Data From AVONEX Dose Titration Study At 2011 Annual Meeting Of The Consortium Of Multipl... http://mnt.to/3WNZ
1 year ago...